OSTX - התחייבויות לטווח ארוך של החברה OS Therapies Inc.

OS Therapies Incorporated (OSTX) is a biopharmaceutical player developing vaccines and targeted therapies to combat osteosarcoma, backed by patent protection and orphan drug status. Historical price action clearly demonstrates market expectations, while the long-term debt figure stands at 0.00. The company's growth relies on OST-HER2 test results and a lack of competitors within this narrow segment. The team's scientific potential ensures shareholder confidence as the company navigates the initial stages of clinical trials.

This indicator measures the aggregate of credit obligations with a maturity of more than one year, allowing for an assessment of the issuer's long-term financial stability and default risk. By analyzing the long-term liabilities of OS Therapies Incorporated (OSTX) on the GURU.Markets platform, an investor can determine whether OS Therapies Incorporated (OSTX) possesses sufficient resources to commercialize the OsteoVax vaccine and develop cancer therapy without a critical debt burden.